Lucie Fransen

Title: Lucie Fransen: Innovating Treatments for Oedema

Introduction

Lucie Fransen, an inventive and dedicated researcher based in Hertsberge, Belgium, has made significant contributions to the medical field through her research and innovation. With a focus on therapeutic peptides, she has developed a pivotal patent that addresses a critical health issue: oedema.

Latest Patents

Lucie holds a unique patent titled "TNF-derived peptides for use in treating oedema." This groundbreaking invention is rooted in the discovery that specific peptides derived from tumor necrosis factor-alpha (TNF-α) are effective in treating oedema. Notably, the patent highlights the usage of circularized peptide with the amino acid sequence CGQRETPEGAEAKPWYC, which has been demonstrated to significantly induce oedema resorption.

Career Highlights

Lucie's professional journey includes her esteemed role at Innogenetics N.V., a company recognized for its innovation in the biotechnology sector. Throughout her career, she has exhibited remarkable determination and expertise, leading to her successful patent which focuses on the therapeutic applications of TNF-derived peptides.

Collaborations

Collaboration is a fundamental aspect of Lucie's work. She has collaborated with notable colleagues, including Rudolf Lucas and Patrick De Baetselier. These partnerships have fostered an environment of creativity and innovation, allowing for the enhancement of research and development within the field of medical therapeutics.

Conclusion

Lucie Fransen's contributions to the field of medicine through her innovative work on TNF-derived peptides are impressive. Her pioneering patent represents a step forward in the treatment of oedema, showcasing how dedicated inventors can have a significant impact on healthcare. Through her ongoing work at Innogenetics N.V. and collaboration with fellow researchers, Lucie continues to push the boundaries of what is possible in medical treatment.